Literature DB >> 24889839

Clinical presentation and patterns of care for short-term survivors of malignant glioma.

Anna Collins1, Vijaya Sundararajan, Caroline A Brand, Gaye Moore, Carrie Lethborg, Michelle Gold, Michael A Murphy, Megan A Bohensky, Jennifer Philip.   

Abstract

Palliative care provision for patients with high-grade malignant glioma is often under-utilised. Difficulties in prognostication and inter-patient variability in survival may limit timely referral. This study sought to (1) describe the clinical presentation of short-term survivors of malignant glioma (survival time <120 days); (2) map their hospital utilisation, including palliative and supportive care service use, and place of death; (3) identify factors which may be important to serve as a prompt for palliative care referral. A retrospective cohort study of incident malignant glioma cases between 2003-2009 surviving <120 days in Victoria, Australia was undertaken (n = 482). Cases were stratified according to the patient's survival status (dead vs. alive) at the end of the diagnosis admission, and at 120 days from diagnosis. Palliative care was received by 78 % of patients who died during the diagnosis admission. Only 12 % of patients who survived the admission and then deteriorated rapidly dying in the following 120 days were referred to palliative care in their hospital admission, suggesting an important clinical subgroup that may miss out on being linked into palliative care services. The strongest predictor of death during the diagnosis admission was the presence of cognitive or behavioural symptoms, which may be an important prompt for early palliative care referral.

Entities:  

Mesh:

Year:  2014        PMID: 24889839     DOI: 10.1007/s11060-014-1483-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  29 in total

1.  What is the evidence that palliative care teams improve outcomes for cancer patients and their families?

Authors:  Irene J Higginson; Catherine J Evans
Journal:  Cancer J       Date:  2010 Sep-Oct       Impact factor: 3.360

2.  New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality.

Authors:  Vijaya Sundararajan; Toni Henderson; Catherine Perry; Amanda Muggivan; Hude Quan; William A Ghali
Journal:  J Clin Epidemiol       Date:  2004-12       Impact factor: 6.437

Review 3.  Neuro-oncology and palliative care: a challenging interface.

Authors:  Esther Lin; Mark A Rosenthal; Brian H Le; Peter Eastman
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

4.  Mapping the patterns of care, the receipt of palliative care and the site of death for patients with malignant glioma.

Authors:  Vijaya Sundararajan; Megan A Bohensky; Gaye Moore; Caroline A Brand; Carrie Lethborg; Michelle Gold; Michael A Murphy; Anna Collins; Jennifer Philip
Journal:  J Neurooncol       Date:  2014-01       Impact factor: 4.130

5.  Perspectives on care at the close of life. Initiating end-of-life discussions with seriously ill patients: addressing the "elephant in the room".

Authors:  T E Quill
Journal:  JAMA       Date:  2000-11-15       Impact factor: 56.272

6.  A study of patients with a primary malignant brain tumour and their carers: symptoms and access to services.

Authors:  Anne Arber; Sara Faithfull; Marek Plaskota; Caroline Lucas; Kay de Vries
Journal:  Int J Palliat Nurs       Date:  2010-01

7.  Barriers to hospice care and referrals: survey of physicians' knowledge, attitudes, and perceptions in a health maintenance organization.

Authors:  Leslea Brickner; Kate Scannell; Stephanie Marquet; Lynn Ackerson
Journal:  J Palliat Med       Date:  2004-06       Impact factor: 2.947

8.  Cancer specialists' palliative care referral practices and perceptions: results of a national survey.

Authors:  C E Johnson; A Girgis; C L Paul; D C Currow
Journal:  Palliat Med       Date:  2008-01       Impact factor: 4.762

9.  End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey.

Authors:  Oliver Heese; Eva Vogeler; Tobias Martens; Oliver Schnell; Jörg-Christian Tonn; Matthias Simon; Johannes Schramm; Dietmar Krex; Gabriele Schackert; Thomas Reithmeier; Guido Nikkhah; Michael Sabel; Hans-Jakob Steiger; Uwe Schlegel; Markus Löffler; Michael Weller; Manfred Westphal
Journal:  Neuro Oncol       Date:  2013-06-28       Impact factor: 12.300

10.  Health care professionals' perspectives of living and dying with primary malignant glioma: Implications for a unique cancer trajectory.

Authors:  Jennifer Philip; Anna Collins; Caroline A Brand; Michelle Gold; Gaye Moore; Vijaya Sundararajan; Michael A Murphy; Carrie Lethborg
Journal:  Palliat Support Care       Date:  2013-10-21
View more
  13 in total

Review 1.  Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.

Authors:  Terri S Armstrong; Allison M Bishof; Paul D Brown; Martin Klein; Martin J B Taphoorn; Christina Theodore-Oklota
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

Review 2.  Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).

Authors:  Jennifer L Helfer; Patrick Y Wen; Jaishri Blakeley; Mark R Gilbert; Terri S Armstrong
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

3.  Frequency and Predictors of Acute Hospitalization Before Death in Patients With Glioblastoma.

Authors:  Eli L Diamond; Katherine S Panageas; Alexis Dallara; Ariel Pollock; Allison J Applebaum; Alan C Carver; Elena Pentsova; Lisa M DeAngelis; Holly G Prigerson
Journal:  J Pain Symptom Manage       Date:  2016-11-01       Impact factor: 3.612

4.  A proposed framework of supportive and palliative care for people with high-grade glioma.

Authors:  Jennifer Philip; Anna Collins; Caroline Brand; Vijaya Sundararajan; Carrie Lethborg; Michelle Gold; Rosalind Lau; Gaye Moore; Michael Murphy
Journal:  Neuro Oncol       Date:  2018-02-19       Impact factor: 12.300

Review 5.  Advance Care Planning in Patients with Primary Malignant Brain Tumors: A Systematic Review.

Authors:  Krystal Song; Bhasker Amatya; Catherine Voutier; Fary Khan
Journal:  Front Oncol       Date:  2016-10-24       Impact factor: 6.244

6.  A randomised phase II trial to examine feasibility of standardised, early palliative (STEP) care for patients with advanced cancer and their families [ACTRN12617000534381]: a research protocol.

Authors:  Jennifer Philip; Anna Collins; Brian Le; Vijaya Sundararajan; Caroline Brand; Susan Hanson; Jon Emery; Peter Hudson; Linda Mileshkin; Soula Ganiatsas
Journal:  Pilot Feasibility Stud       Date:  2019-03-14

Review 7.  Palliative Care in High-Grade Glioma: A Review.

Authors:  Rita C Crooms; Nathan E Goldstein; Eli L Diamond; Barbara G Vickrey
Journal:  Brain Sci       Date:  2020-10-13

Review 8.  Prevalence of changes in personality and behavior in adult glioma patients: a systematic review.

Authors:  Hanneke Zwinkels; Linda Dirven; Thomas Vissers; Esther J J Habets; Maaike J Vos; Jaap C Reijneveld; Martin J van den Bent; Martin J B Taphoorn
Journal:  Neurooncol Pract       Date:  2015-09-29

9.  I-CoPE: A pilot study of structured supportive care delivery to people with newly diagnosed high-grade glioma and their carers.

Authors:  Jennifer Philip; Anna Collins; Jane Staker; Michael Murphy
Journal:  Neurooncol Pract       Date:  2018-05-19

10.  Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocol.

Authors:  Jennifer Philip; Roslyn Le Gautier; Anna Collins; Anna K Nowak; Brian Le; Gregory B Crawford; Nicole Rankin; Meinir Krishnasamy; Geoff Mitchell; Sue-Anne McLachlan; Maarten IJzerman; Robyn Hudson; Danny Rischin; Tanara Vieira Sousa; Vijaya Sundararajan
Journal:  BMC Health Serv Res       Date:  2021-05-27       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.